Potential Blockbuster Drugs to Watch
In some recent publications I’ve been reading, I came across a list of some compounds that may become blockbusters (sales of more than $1 billion a year). I found it interesting and wanted to post the list here. These are all already filed or in late phase III trials.
| Drug | Company | Indication | Type |
|---|---|---|---|
| Acomplia | Sanofi-Aventis | weight-loss | small molecule |
| Actemra | Roche | rheumatoid arthritis | biologic |
| CERA * | Roche | anemia | ? |
| Galvus | Novartis | type 2 diabetes | small molecule |
| Paliperidone | Johnson & Johnson | schizophrenia | small molecule |
| Panitumumab | Amgen | colorectal cancer | biologic |
| Prasugrel | Eli Lilly | antiplatelet agent | small molecule |
| Rasilez | Novartis | hypertension | small molecule |
| TAK-390MR | Abbott | night time hearburn (GERD) | small molecule |
| Torcetrapib/atorvastatin | Pfizer | cholesterol | small molecule combo |
• = Continuous Erythropoiesis Receptor Activator
It is interesting that Roche is the only company with two compounds on this list.
Search results for each drug from Yahoo!
• acomplia
• actemra
• cera “Continuous Erythropoiesis Receptor Activator”
• galvus
• paliperidone
• panitumumab
• prasugrel
• rasilez
• TAK-390MR
• torcetrapib atorvastatin
Technorati Tags: blockbuster drugs
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
